Recently, the first national multicenter epidemiological investigation and research project of metabolic fatty liver disease (MAFLD) in China was announced to have completed the enrollment. The study included more than 2000 subjects in the group, covering more than 30 centers in 11 cities. It only took three months from the start of the project to the completion of enrollment.
The project has been launched online on May 11, 2022 The project was jointly initiated by China Liver Health (CLH) and Tsinghua Changgeng Hospital, and funded by Pfizer China. It was carried out based on a wide range of people in Meinian Health Examination Center and the digital platform of innovative clinical CRO Aisha Medicine, and pioneered the integration model of physical examination service+device detection+medical service. The purpose is to comprehensively understand the epidemic situation of MAFLD in China, fill in the gaps in the field, and promote the development of diagnosis and treatment. MAFLD causes great harm, epidemiology lays the foundation Metabolic associated fatty liver disease (MAFLD) is the most common chronic liver disease in the world. Its incidence is increasing year by year in China. It is associated with liver cancer, cardiovascular disease, type II diabetes and other diseases, and has great harm. However, the pathogenesis of MAFLD is still uncertain, and there is no corresponding therapeutic drug. Epidemiological investigation is the cornerstone of disease prevention and control. Through the discovery of disease related risk factors and the early intervention of the risk population, the incidence of disease can be reduced, and medical evidence can be provided for the later clinical research to explore the pathological mechanism and study the corresponding therapeutic drugs. In May 2022, under the leadership of Professor Wei Lai from Tsinghua Changgeng Hospital, the first large-scale "MAFLD Epidemiological Investigation and Research Project" in China was launched. As a very important basic research, it is expected to fill the gap of MAFLD epidemiological data in China and play a far-reaching role in future disease management, drug research and development, even health management, medical resource planning and other aspects, with great academic value and practical significance. Multi party cooperation and innovation mode to ensure efficient research In terms of project development form, this MAFLD epidemiological survey and research pioneered a new clinical research model jointly promoted by social organizations, hospitals, health management centers and clinical research companies, bringing new exploration ideas for the future clinical research development model. The study was conducted in more than 30 Meinian Health Examination Centers in 11 cities across the country, reaching a wide range of potential people and forming an accurate transformation, reducing the cost of enrolling subjects. Adhering to the guiding principle of "patient-centered" and integrating physical examination services, device testing and medical services, the researchers will get high value examination items free of charge, without the need for repeated blood drawing, and can also get targeted health guidance, follow-up suggestions and green medical channels of local hospitals after finding relevant liver problems, so as to maximize the benefits of the subjects and greatly improve their willingness to join the group. In terms of subject data management, with the help of Aisha Medical's digital platform and the application of AI semantic recognition and other intelligent collection tools, the test data collection was completed quickly and accurately, and a remote multi center collaborative management system was built, which further improved the efficiency of subject management. In the case of many inconveniences caused by the epidemic, this project can ensure such a rapid speed of participation, which is inseparable from the joint efforts of all project participants and the full support of all social parties! It is expected that the research results will be produced as soon as possible, which will bring hope to solve the unmet clinical needs of patients with MAFLD in China. |
关注官方微信 
